Our Pricing

Complete Wegovy Doses Chart for UK Weight Loss Treatment

Understanding the wegovy doses chart uk is essential for anyone starting semaglutide weight loss treatment. At Cured Pharmacy, we provide clear guidance on each dose level, from your initial 0.25mg injection through to the full maintenance dose, ensuring you know exactly what to expect throughout your treatment journey.

Understanding the Wegovy Doses Chart UK Titration Schedule

Wegovy follows a carefully structured dose escalation schedule designed to minimise gastrointestinal side effects whilst building therapeutic levels of semaglutide in your system [1]. The UK-licensed dosing protocol begins at 0.25mg weekly and gradually increases over 16 weeks until you reach the maintenance dose of 2.4mg.

This gradual titration is clinically proven to improve tolerability. In the STEP 1 trial, patients following the standard dose escalation schedule reported significantly fewer discontinuations due to adverse events compared to those who escalated more rapidly [1]. Each dose level is maintained for exactly four weeks before progressing to the next strength.

The complete wegovy doses chart uk includes five escalation phases: 0.25mg (month 1), 0.5mg (month 2), 1mg (month 3), 1.7mg (month 4), and 2.4mg (month 5 onwards). Missing doses or attempting to skip levels can increase your risk of nausea, vomiting, and other gastrointestinal symptoms, which is why adherence to the prescribed schedule is essential [2].

What Happens If You Miss a Dose

If you miss a Wegovy injection and it has been fewer than two days since your scheduled dose, administer it as soon as you remember. If more than two days have passed, skip that dose entirely and resume your normal schedule with your next planned injection [3]. Never double up doses to compensate for a missed injection, as this significantly increases the risk of severe nausea and vomiting.

Wegovy Starting Dose UK: The 0.25mg Phase Explained

Your first four Wegovy injections will each contain 0.25mg of semaglutide. This initial dose is not designed for significant weight loss—it serves as a conditioning phase that allows your body to adapt to the medication's effects on gastric emptying and appetite regulation [1].

During this first month, many patients report reduced appetite and earlier satiety, though weight loss is typically modest at this stage. Clinical trial data shows an average weight reduction of 1-2% during the 0.25mg phase, with the primary benefit being excellent tolerability as your body adjusts [2].

Common experiences at 0.25mg include mild nausea (usually resolving within 2-3 days), reduced portion sizes at meals, and decreased food cravings. These effects indicate the medication is working as intended. Your UK prescriber may advise staying on this dose for longer than four weeks if you experience persistent gastrointestinal symptoms, though this is uncommon.

Wegovy Injection Strength Progression: 0.5mg to 1.7mg Doses

After completing your initial month at 0.25mg, you progress to 0.5mg weekly for the next four weeks. This is where many patients begin noticing more substantial weight loss, with clinical trials reporting an average 5-8% body weight reduction by the end of the 0.5mg phase [1].

The 1mg dose, administered during weeks 9-12 of treatment, represents a significant therapeutic threshold. STEP trial data demonstrates that patients reaching 1mg consistently show enhanced glycaemic control and sustained appetite suppression, with average weight loss accelerating to approximately 10-12% of baseline body weight by week 12 [2].

Your penultimate dose of 1.7mg (weeks 13-16) bridges the gap to full maintenance therapy. Some patients find this dose provides optimal balance between efficacy and tolerability, and UK prescribers may recommend remaining at 1.7mg if the 2.4mg dose proves difficult to tolerate. Research indicates that 1.7mg delivers approximately 85-90% of the weight loss effect seen at the full 2.4mg maintenance dose [3].

Recognising When to Escalate Doses

You should only progress to the next wegovy doses chart uk level after completing a full four weeks at your current strength and confirming tolerability with your prescriber. Signs you are ready to escalate include minimal or resolved gastrointestinal symptoms, stable adherence to your injection schedule, and no concerning side effects requiring medical review.

The 2.4mg Maintenance Dose: Long-Term Weight Management

Reaching the 2.4mg maintenance dose marks the beginning of your long-term weight management phase. This is the dose at which Wegovy demonstrated its landmark results in the STEP programme, with participants achieving an average 14.9% body weight reduction over 68 weeks [1].

Once established on 2.4mg, most patients continue this dose indefinitely as part of a comprehensive weight management programme. Clinical data from the STEP 4 trial showed that patients who discontinued Wegovy after reaching their maintenance dose regained approximately two-thirds of their lost weight within one year, underscoring the medication's role as a long-term treatment rather than a short-term intervention [2].

At Cured Pharmacy, Wegovy is available from £79.00 per month, with transparent pricing shown before your free consultation. Our UK-registered prescribers assess your eligibility and determine your appropriate dosing schedule based on your medical history, current medications, and weight management goals. All prescription treatments require clinical assessment by a UK prescriber, and genuine UK-licensed medicines are dispensed by our GPhC-registered pharmacy team led by Superintendent Pharmacist Tarun Kumar (GPhC 2233073).

Wegovy Dosing Schedule UK: Managing Side Effects at Each Level

Gastrointestinal symptoms are the most frequently reported side effects across all dose levels, with nausea affecting approximately 44% of patients in clinical trials, though most cases are mild to moderate and resolve within several weeks [3]. The structured titration schedule significantly reduces the severity and duration of these symptoms compared to starting at higher doses.

At lower doses (0.25mg and 0.5mg), nausea and reduced appetite are most common. By the 1mg and 1.7mg phases, constipation becomes more prevalent, affecting roughly 24% of patients [3]. The maintenance 2.4mg dose may initially intensify these effects temporarily before your body fully adjusts, typically within 2-4 weeks.

Practical strategies to minimise side effects include eating smaller, more frequent meals, avoiding high-fat foods that delay gastric emptying further, staying well-hydrated, and timing your injection consistently on the same day each week. If symptoms persist or worsen, contact your prescriber—dose adjustments or temporary holds may be appropriate rather than discontinuing treatment entirely.

When to Contact Your Prescriber

Seek immediate medical advice if you experience severe abdominal pain that does not resolve, persistent vomiting preventing fluid intake, signs of pancreatitis (severe upper abdominal pain radiating to your back), or symptoms of thyroid tumours (lump in neck, difficulty swallowing, persistent hoarseness). These are rare but serious adverse events requiring prompt clinical assessment [3].

Wegovy Doses Chart UK: Maximising Your Treatment Success

Adherence to your prescribed wegovy doses chart uk schedule is the single strongest predictor of successful long-term weight loss. Analysis of real-world data shows that patients who maintain consistent weekly injections without gaps achieve 3-4 times greater weight reduction compared to those with irregular dosing patterns [2].

Wegovy works most effectively when combined with reduced-calorie nutrition and increased physical activity. The STEP trials required participants to follow a 500-calorie daily deficit and engage in at least 150 minutes of moderate exercise weekly [1]. Patients who implemented these lifestyle modifications alongside medication achieved significantly better outcomes than those relying on pharmacotherapy alone.

Regular monitoring with your UK prescriber ensures your treatment remains safe and effective. Typical follow-up schedules include assessments at 4 weeks, 12 weeks, and then every 12 weeks thereafter. Your prescriber will evaluate weight loss progress, review any side effects, check for contraindications, and adjust your treatment plan as needed. At Cured Pharmacy, our clinical team provides ongoing support throughout your weight management journey, with all consultations conducted by UK-registered healthcare professionals.

Setting Realistic Weight Loss Expectations

Clinical guidelines suggest aiming for 5-10% body weight reduction in the first 3-6 months of treatment, with continued gradual loss thereafter [2]. Not everyone responds identically to semaglutide—approximately 86% of patients achieve at least 5% weight loss, whilst around 50% reach 15% or greater reduction [1]. Your individual response depends on multiple factors including baseline weight, adherence, lifestyle modifications, and metabolic factors.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
2. Rubino, D., Abrahamsson, N., Davies, M., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224
3. Novo Nordisk. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Electronic Medicines Compendium. Retrieved from https://www.medicines.org.uk/emc/product/13799

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy is a prescription-only medicine in the UK and must be prescribed following appropriate clinical evaluation of your medical history, current health status, and suitability for treatment.